Protocol for the Redefining Maternal Anemia in Pregnancy and Postpartum (ReMAPP) study: A multisite, international, population-based cohort study to establish global hemoglobin thresholds for maternal anemia

Emily R. Smith,Zahra Hoodbhoy,Aneeta Hotwani,Fyezah Jehan,Amna Khan,Imran Nisar,Nida Yazdani,Santosh Joseph Benjamin,Anne George Cherian,Venkata Raghava Mohan,Sunitha Varghese,Balakrishnan Vijayalekshmi,Blair J. Wylie,Leena Chatterjee,Arjun Dang,R Venketeshwar,Sasha Glass Baumann,Christopher Mores,Qing Pan,Christopher R. Sudfeld,Victor Akelo,Winnie K. Mwebia,Kephas Otieno,Gregory Ouma,Harun Owuor,Joyce Akinyi Were,Dennis Adu-Gyasi,Veronica Agyemang,Kwaku Poku Asante,Sam Newton,Charlotte Tawiah,Arun Singh Jadaun,Sarmila Mazumder,Neeraj Sharma,Lynda G. Ugwu,Amma Benneh-Akwasi Kuma,Bethany Freeman,Margaret P. Kasaro,Felistas M. Mbewe,Humphrey Mwape,Rachel S. Resop,M. Bridget Spelke
DOI: https://doi.org/10.1101/2024.11.06.24316823
2024-11-06
Abstract:Background: Anemia affects one in three pregnant women worldwide, with the greatest burden in South Asia and sub-Saharan Africa. During pregnancy, anemia has been linked to an increased risk of adverse maternal and neonatal health outcomes. Despite widespread recognition that anemia can complicate pregnancy, critical gaps persist in our understanding of the specific causes of maternal anemia and the cutoffs used to diagnose anemia in each trimester and in the postpartum period. Methods and analysis: The Redefining Maternal Anemia in Pregnancy and Postpartum (ReMAPP) study is a multisite, prospective, cohort study nested within the Pregnancy Risk, Infant Surveillance, and Measurement Alliance (PRISMA) Maternal and Newborn Health study. Research sites are located in Kenya, Ghana, Zambia, India, and Pakistan. Participants are up to 12,000 pregnant women who provide serial venous blood samples for hemoglobin assessment at five time points: at <20 weeks, 20 weeks, 28 weeks, and 36 weeks gestation and at six weeks postpartum. We will use two analytical approaches to estimate hemoglobin thresholds for defining anemia: (1) clinical decision limits for cutoffs in each trimester and at six weeks postpartum based on associations of hemoglobin levels with adverse maternal, fetal, and neonatal health outcomes and (2) reference limits for gestational-week-specific cutoffs and at six weeks postpartum for mild, moderate, and severe anemia based on tail statistical percentiles of hemoglobin values in a reference (i.e., clinically healthy) subpopulation. We will also conduct biomarker-intensive testing among a sub-sample of participants in each trimester to explore underlying contributing factors of maternal anemia. Ethics and dissemination: The study received local and national ethical approvals from all participating institutions. Findings from multisite analyses will be published among open-access, peer-reviewed journals and disseminated with local, national, and international partners.
Public and Global Health
What problem does this paper attempt to address?